Commentary: Medicare is cleaning up FDA's mess on Biogen's Alzheimer's drug
By clarifying what evidence it needs before it will pay for medicines like Aduhelm, the agency paved the way for improved drug innovation. |!| Portland
By clarifying what evidence it needs before it will pay for medicines like Aduhelm, the agency paved the way for improved drug innovation. |!| Portland